Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herombopag in Elderly ITP
NCT06838949Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hetrombopag in immune thrombocytopenia (ITP), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Proportion of patients with platelet count ≥30×10^9/L at 8 weeks. Started Mar 2025; status: recruiting.
02
Drugs
hetrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06838949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06838949.